CAMPAIGNERS have urged Scotland's medicines regulator to reverse a decision to reject a new drug for patients with MS after the equivalent body south of the Border approved the same pill.
The Scottish Medicines Consortium (SMC) said the makers of fingolimod, the first tablet treatment for MS, did not show it was good value for money and the body chose not to recommend it for use on the NHS.
But now the National Institute for Health and Clinical Excellence (Nice), which rules on drugs in England and Wales, has revealed draft guidance recommending fingolimod, whose brand name is Gilenya, for prescription on the NHS for some patients with relapsing-remitting multiple sclerosis.
It raises the prospect of a north-south divide for patients, even although Scotland suffers the highest rate of MS in the world, with 10,500 people diagnosed with the condition.
Dr Belinda Weller, a neurologist at the Western General in Edinburgh who led the Scottish clinical trial of fingolimod, said: "It's going to be quite hard for our patients in Scotland who are aware that people over the Border are going to be having access to this.
"But I'm also hopeful that with that decision there will be more pressure on the regulatory body in Scotland to reconsider the decision."
Fingolimod can help reduce the number of relapses in adults with relapsing-remitting multiple sclerosis.
A spokesman for the SMC said: "Sometimes SMC has to make very difficult decisions and we are acutely aware that our decisions have an impact on patients."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article